Pharmafile Logo

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear…

“…Of course, we also need to consider where (from who) the information is coming from. Doctors, pharmacists, and other health experts are more trusted than life science CEOs, government leaders, and journalists. Among healthcare institutions, academic medical research institutions are the most trusted. For Pharma, this means that establishing authentic relationships with trusted and approachable physicians, pharmacists, nurses, and academics should be a top priority. In addition to traditional key opinion leaders (KOLs), digital opinion leaders (DOLs)–an emerging group of stakeholders for Pharma to engage with–are well-positioned to share scientific data with the general public. 

Pharma teams should work directly with KOLs and DOLs, as well as with patients and caregivers, to design public-facing videos, websites, handouts, and educational campaigns in order to get the right messages across. When events that might erode public trust do occur, be open and honest with your advisors and get their input on how to respond to negative press in a transparent and sincere manner.”

Read the full article at https://www.impetusdigital.com/2022/05/10/trust-and-transparency-in-pharma/

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

The New Normal: Upcoming Trends in Clinical Trials

Samuel Searcy, Founder & CEO of CliniStart, shares his expert insights into trends, current gaps, and future predictions for clinical trials. Among many other things, we also dive into his...

Digitizing Cardiac Rehab to Capture and Retain More Patients

Dr. Harsh Vathsangam, CEO & Co-Founder of Moving Analytics, shares his expertise on mobile health and discusses how it can be used to improve patient adherence and access to cardiac...

Lesson Learned from the Pandemic

Tom Hsu, VP of Specialty Medicine at Bayer Canada, talks about how he got to where he is today and his experience working for Bayer in China and how that...

The Ongoing Evaluation of Medical Affairs

Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer, discusses a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work...

Innovation in Research, Digital Solutions and Patient Engagement

Craig Lipset, Founder and Advisor at Clinical Innovation Partners and former Head of Clinical Innovation and Venture Partner at Pfizer, talks about everything from his personal health journey to his...

Transforming Healthcare Through the Power of Patients

Esther Schorr, Co-founder and Chief Operating Officer of Patient Power LLC, discusses non-linear journey to patient education and Patient Power's mission to empower patients and their loved ones to take...

Global Marketing, Technology, and Innovation

Jim Lefevere, Director of Global Marketing Services at Roche, discusses the changes in digital marketing strategies, workflow, team dynamics, and required skill sets among Pharma teams brought on by COVID-19....

Train Your Brain for Success

Max Newlon, President of Brain Co., discusses everything from meditation practices and behavioral science to the use of technology in assessing and treating mental health conditions. He also delves into...

Amplifying Data Science Tools for End-to-End eClinical Solutions

Andreas Weber, Group CEO, EvidentIQ, discusses hybrid vs. fully decentralized trials, the use of real-world evidence (RWE) in clinical trials, and how an end-to-end eClinical solution can help meet increasing...

Virtual meeting technologies for reducing emissions and waste in the healthcare industry

Read the full article here or on the Green Business Bureau blog for more details.